Currently, the endotype-driven strategies for asthma management use several biologic therapies targeting a specific pathogenetic pathway: anti IgE (omalizumab), anti IL-4/IL-13 (dupilumab), anti IL-5 (benralizumab, depemokimab, mepolizumab, reslizumab), TSLP (tezepelumab), IL-33/ST2 (itepekimab, tozorakimab, astegolimab) (14, 42, 43). This evidence concerns the gene TSLP and asthma.